UCB

biopharmaceutical company headquartered in Brussels, Belgium

UCB Euronext Brussels · home listing UCBJF OTC Markets Group ISIN BE0003739530 LEI 2138008J191VLSGY5A09
Follow UCB Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2024 EUR · IFRS
Revenue, last year €6.2B +17.1% vs prior year
Net income €1.1B +210.5% vs prior year
EPS, diluted €5.48 +211.4% vs prior year
Operating cash flow €1.2B +63.2% vs prior year
Revenue by fiscal year
€5.3B
€5.8B
€5.5B
€5.3B
€6.2B
FY20 FY21 FY22 FY23 FY24

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income5 fiscal years
  • Revenue
  • Net income
€0€2B€4B€6B€8BFY20FY21FY22FY23FY24
Show the numbers
YearRevenueNet income
FY24€6.2B€1.1B
FY23€5.3B€343M
FY22€5.5B€418M
FY21€5.8B€1.1B
FY20€5.3B€732M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%20%40%60%80%FY20FY21FY22FY23FY24
Show the numbers
YearGross marginOperating marginNet margin
FY2471.5%21.5%17.3%
FY2367.5%11.5%6.5%
FY2269.7%10.6%7.6%
FY2175.1%22.2%18.3%
FY2074.5%18.2%13.7%
Free cash flowOperating cash flow minus capital expenditure
€0€500M€1B€1.5BFY20FY21FY22FY23FY24
Show the numbers
YearFree cash flow
FY24€1B
FY23€523M
FY22€867M
FY21€1.3B
FY20€825M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
€0€200M€400M€600MFY20FY21FY22FY23FY24
Show the numbers
YearDividendsBuybacks
FY24€259M€162M
FY23€252M€40M
FY22€247M€42M
FY21€240M€60M
FY20€235M€106M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • UCB
  • Healthcare median
−100%−75%−50%−25%0%25%FY20FY21FY22FY23FY24
Show the numbers
YearUCBHealthcare median
FY2417.3%−47%
FY236.5%−58%
FY227.6%−80.4%
FY2118.3%−71.9%
FY2013.7%−62.2%